Peptide therapy has become a central tool in modern medical weight management. This guide is written for clinicians expanding their metabolic services and outlines the protocols, safety considerations, and monitoring practices we see used in successful regenerative and functional medicine practices.
Why peptides for weight loss
Weight loss peptides work through several overlapping mechanisms: appetite regulation (GLP-1/GIP receptor agonists), improved insulin sensitivity, increased lipolysis via growth hormone axis modulation, and enhanced satiety signaling. Compared with legacy pharmacotherapy, current agents deliver 10–22% total body weight loss in trial populations with a manageable side-effect profile when properly titrated.
Core agents
1. GLP-1 receptor agonists
- Semaglutide — weekly SC. Typical titration: 0.25 mg wk 1–4, 0.5 mg wk 5–8, escalating to 1.0–2.4 mg based on tolerance and response.
- Tirzepatide (GLP-1/GIP) — weekly SC. Titration from 2.5 mg → up to 15 mg. Superior weight loss vs. semaglutide in head-to-head data.
2. Growth hormone secretagogues
- CJC-1295 / Ipamorelin — nightly SC. Supports lipolysis, lean-mass preservation, and sleep quality during caloric restriction.
- Tesamorelin — FDA-approved for visceral adiposity; particularly useful for central obesity phenotypes.
3. Adjuncts
- AOD-9604 — fragment of hGH; targeted lipolysis without full GH effects.
- MOTS-c — mitochondrial-derived peptide supporting metabolic flexibility and insulin sensitivity.
Patient selection
Appropriate candidates typically meet BMI ≥ 27 with a comorbidity or BMI ≥ 30, have failed structured lifestyle intervention, and understand this is a long-term metabolic therapy — not a short course. Baseline workup should include CMP, lipid panel, HbA1c, fasting insulin, TSH, and (for GH secretagogues) IGF-1.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN-2 (GLP-1 class).
- Active pancreatitis, severe gastroparesis, or pregnancy.
- Active malignancy for GH-axis peptides.
- Uncontrolled diabetic retinopathy — rapid weight loss can worsen progression.
Monitoring cadence
- Weeks 0–12: monthly weight, GI tolerability, and dose titration check-ins.
- Quarterly: CMP, HbA1c, lipids, body composition (DEXA or BIA).
- Annually: IGF-1 (for GH secretagogues), thyroid panel, cardiovascular risk reassessment.
Common pitfalls
- Escalating too quickly — most GI side effects are titration-related.
- Neglecting resistance training and protein intake (≥1.2 g/kg) leads to lean-mass loss.
- Stopping therapy abruptly — expect regain; plan a maintenance dose or structured taper.
- Sourcing from non-verified compounders — supply quality is the #1 clinical risk factor.
Building the service line
A defensible peptide weight-loss program combines validated intake, physician-supervised dosing, verified sourcing, and structured follow-up. Practices that pair peptides with body composition tracking and nutrition coaching see the strongest retention and outcomes.
Explore related resources: AI-powered peptide protocols · Biologics · Back to blog